Close

BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints

Go back to BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints
(NASDAQ: BGNE) Delayed: 168.50 -1.5 (0.88%)
Previous Close $170.00    52 Week High $36.76 
Open $168.33    52 Week Low $22.51 
Day High $170.78    P/E N/A 
Day Low $168.33    EPS $0.00 
Volume 154,982